Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 3, pp. 1211-1228
Open Access | Times Cited: 266

Showing 26-50 of 266 citing articles:

Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Kyle M. Garland, Taylor L. Sheehy, John T. Wilson
Chemical Reviews (2022) Vol. 122, Iss. 6, pp. 5977-6039
Open Access | Times Cited: 203
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Lena Horvath, Bernard Thienpont, Liyun Zhao, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 194
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud, Antoîne Italiano
Cancers (2020) Vol. 12, Iss. 6, pp. 1502-1502
Open Access | Times Cited: 180
Immunomodulation by targeted anticancer agents
Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, et al.
Cancer Cell (2020) Vol. 39, Iss. 3, pp. 310-345
Open Access | Times Cited: 179
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 16, pp. 4268-4279
Open Access | Times Cited: 167
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein, Chirag Krishna, Xiaoxiao Ma, et al.
Nature Cancer (2020) Vol. 1, Iss. 12, pp. 1188-1203
Open Access | Times Cited: 153
Old dogs, new trick: classic cancer therapies activate cGAS
Seoyun Yum, Minghao Li, Zhijian J. Chen
Cell Research (2020) Vol. 30, Iss. 8, pp. 639-648
Open Access | Times Cited: 141
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Giulia Petroni, Lewis C. Cantley, Laura Santambrogio, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 114-131
Open Access | Times Cited: 138
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Qiwei Wang, Johann S. Bergholz, Liya Ding, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 136
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Mengting Chen, Renske Linstra, Marcel A.T.M. van Vugt
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1877, Iss. 1, pp. 188661-188661
Open Access | Times Cited: 117
Prostate cancer and PARP inhibitors: progress and challenges
Diego Teyssonneau, Henri Margot, Mathilde Cabart, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 110
Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect
Chao Wang, Zhaoyi Sun, Chenxuan Zhao, et al.
Journal of Controlled Release (2021) Vol. 331, pp. 480-490
Closed Access | Times Cited: 103
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 440-462
Closed Access | Times Cited: 96
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Itziar Otano, Álvaro C. Ucero, Jon Zugazagoitia, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 3, pp. 143-159
Closed Access | Times Cited: 82
Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity
Lan Fang, Yun Hao, Haihong Yu, et al.
Cancer Cell (2023) Vol. 41, Iss. 6, pp. 1118-1133.e12
Open Access | Times Cited: 56
The DNA Damage Response and Inflammation in Cancer
Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1521-1545
Open Access | Times Cited: 54
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
Liya Ding, Qiwei Wang, Antons Martincuks, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005627-e005627
Open Access | Times Cited: 50
The complementarity of DDR, nucleic acids and anti-tumour immunity
Anand Kornepati, Cody M. Rogers, Patrick Sung, et al.
Nature (2023) Vol. 619, Iss. 7970, pp. 475-486
Closed Access | Times Cited: 46
Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation
Wei Xiang, Hongwei Lv, Fuxue Xing, et al.
Science Advances (2023) Vol. 9, Iss. 49
Open Access | Times Cited: 46
cGAS–STING, an important signaling pathway in diseases and their therapy
Qijie Li, Ping Wu, Qiujing Du, et al.
MedComm (2024) Vol. 5, Iss. 4
Open Access | Times Cited: 21
IRF3 activates RB to authorize cGAS-STING–induced senescence and mitigate liver fibrosis
Qirou Wu, Xiaohong Leng, Qian Zhang, et al.
Science Advances (2024) Vol. 10, Iss. 9
Open Access | Times Cited: 20
Prospects for combining immune checkpoint blockade with PARP inhibition
Anping Li, Ming Yi, Shuang Qin, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 119
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Aitziber Buqué, Norma Bloy, María Pérez-Lanzón, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 101
PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
Chiho Kim, Xudong Wang, Yonghao Yu
eLife (2020) Vol. 9
Open Access | Times Cited: 98
Replication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response
Sandrine Ragu, Gabriel Matos‐Rodrigues, Bernard S. López
Genes (2020) Vol. 11, Iss. 4, pp. 409-409
Open Access | Times Cited: 88

Scroll to top